AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34857236 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 31
Study 34857236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34857357 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT measured before and days 0-3 after surgery
Number of subjects: 1291
Study 34857357 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT thresholds evaluated
Number of subjects: 1291
Study 34857357 — intervention group
Group type: COMPARATOR
Intervention: Revised Cardiac Risk Index (RCRI)
Number of subjects: 1291
Study 34857432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 396 days post-MI
Number of subjects: 7708
Study 34857432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 5 years post-MI
Number of subjects: 7708
Study 34857432 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT use in relation to age and treatment type
Number of subjects: 7708
Study 34857432 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic variations in DAPT use
Number of subjects: 7708
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic motor dysfunction (n=40, 59%)
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated transaminases (n=7, 10%)
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute/intermittent symptoms (n=21, 31%)
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile illness-associated acute weakness
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (n=68)
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptom onset in the 1970s
Number of subjects: 68
Study 34857438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptom onset after 2000
Number of subjects: 68
Study 34857473 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry of secondary revascularization (REVASEC)
Number of subjects: 0
Study 34857473 — intervention group
Group type: EXPERIMENTAL
Intervention: Management including medical treatment and secondary revascularization (SR)
Number of subjects: 0
Study 34857533 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 29
Study 34857554 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding promotion tailored to meet the nutritional needs of LBW infants
Number of subjects: 12
Study 34857554 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort study
Number of subjects: 12
Study 34857584 — intervention group
Group type: EXPERIMENTAL
Intervention: CCEDRRN COVID-19 Infection Score derived from 21,743 patients
Number of subjects: 27665
Study 34857584 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of CCEDRRN COVID-19 Infection Score in 5,295 patients
Number of subjects: 27665
Study 34857585 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion during liver transplantation surgery
Number of subjects: 30
Study 34857585 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during liver transplantation surgery
Number of subjects: 30
Study 34857656 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line immunochemotherapy
Number of subjects: 0
Study 34857656 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not achieving CMR
Number of subjects: 0
Study 34857658 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase-type plasminogen activator receptor (uPAR) PET/CT
Number of subjects: 0
Study 34857658 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34857666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 934
Study 34857666 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 934
Study 34857684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 0
Study 34857814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota in girls during puberty
Number of subjects: 148
Study 34857814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota in boys during puberty
Number of subjects: 148
Study 34857814 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of estrogen-metabolizing Clostridia in both sexes
Number of subjects: 148
Study 34857814 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cephalosporins prior to age 10 in girls
Number of subjects: 148
Study 34857877 — intervention group
Group type: EXPERIMENTAL
Intervention: ELBW cases
Number of subjects: 180
Study 34858178 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with antiangiogenic therapy
Number of subjects: 0
Study 34858178 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34858205 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based high-intensity interval training (Home-HIIT)
Number of subjects: 0
Study 34858205 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 0
Study 34858350 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step screening strategy with GCT
Number of subjects: 1804
Study 34858350 — intervention group
Group type: COMPARATOR
Intervention: One-step screening strategy with OGTT
Number of subjects: 1804
Study 34858350 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step screening with OGTT
Number of subjects: 1804
Study 34858350 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step screening with GCT
Number of subjects: 1804
Study 34858423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic Cell-Based HIV Vaccine in combination with Pegylated Interferon α-2a
Number of subjects: 29
Study 34858423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 34858433 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off (MCO) membranes
Number of subjects: 0
Study 34858433 — intervention group
Group type: COMPARATOR
Intervention: High-Flux (HF) membranes
Number of subjects: 0
Study 34858523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (gln) powder 15 g bid for the full duration of treatment
Number of subjects: 72
Study 34858805 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective radical resection of advanced digestive system cancer
Number of subjects: 839
Study 34858805 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 839
Study 34858829 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant concurrent chemoradiotherapy (nCRT)
Number of subjects: 149
Study 34858829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 149
Study 34858837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency irreversible electroporation (H-FIRE) ablation
Number of subjects: 110
Study 34859035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 0
Study 34859035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 34859043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Track protocol in minimally invasive gynecology
Number of subjects: 0
Study 34859043 — intervention group
Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 0
Study 34859113 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin
Number of subjects: 177
Study 34859113 — intervention group
Group type: COMPARATOR
Intervention: Single dose of cefazolin
Number of subjects: 177
Study 34859113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of prophylaxis
Number of subjects: 177
Study 34859204 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft shoe version
Number of subjects: 800
Study 34859204 — intervention group
Group type: COMPARATOR
Intervention: Hard shoe version
Number of subjects: 800
Study 34859288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the laryngeal motor cortex (LMC)
Number of subjects: 13
Study 34859288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 13
Study 34859498 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subthalamotomy
Number of subjects: 86
Study 34859498 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 86
Study 34859612 — intervention group
Group type: COMPARATOR
Intervention: GLPG1972 (≤2100 mg [fasted] and 300 mg [fed] single doses; ≤1050 mg once daily [fed] for 14 days)
Number of subjects: 159
Study 34859612 — intervention group
Group type: COMPARATOR
Intervention: GLPG1972 (≤300 mg once daily [fed] for 4 weeks)
Number of subjects: 159
Study 34859612 — intervention group
Group type: COMPARATOR
Intervention: GLPG1972 (≤1500 mg single dose for Japanese; 300 mg single dose for White; ≤1050 mg once daily for Japanese; 300 mg once daily for White for 14 days)
Number of subjects: 159
Study 34860120 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Number of subjects: 0
Study 34860130 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Gamification
Number of subjects: 0
Study 34860130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34860418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LNF (≥75 mg po bid + RTV) for 12 weeks
Number of subjects: 55
Study 34860418 — intervention group
Group type: EXPERIMENTAL
Intervention: All-oral low-dose LNF (25 or 50 mg po bid + RTV) for 24 weeks
Number of subjects: 55
Study 34860418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination low-dose LNF (25 or 50 mg po bid + RTV + PEG-IFNα) for 24 weeks
Number of subjects: 55
Study 34860739 — intervention group
Group type: COMPARATOR
Intervention: Iopromide administration in children
Number of subjects: 132850
Study 34860739 — intervention group
Group type: COMPARATOR
Intervention: Iopromide administration in elderly
Number of subjects: 132850
Study 34860739 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide administration in adults
Number of subjects: 132850
Study 34860739 — intervention group
Group type: COMPARATOR
Intervention: Overall iopromide administrations in children
Number of subjects: 132850
Study 34860739 — intervention group
Group type: COMPARATOR
Intervention: Overall iopromide administrations in elderly
Number of subjects: 132850
Study 34860739 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall iopromide administrations in adults
Number of subjects: 132850
Study 34860815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic Quantitative Sensory Testing (P-QST)
Number of subjects: 0
Study 34860815 — intervention group
Group type: EXPERIMENTAL
Intervention: P-QST
Number of subjects: 0
Study 34861073 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 6
Study 34861073 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous circadian rhythms
Number of subjects: 6
Study 34861146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic endoderm cells (PECs) implanted subcutaneously with immunosuppressive regimen
Number of subjects: 15
Study 34861151 — intervention group
Group type: EXPERIMENTAL
Intervention: Add on heart failure therapy
Number of subjects: 0
Study 34861151 — intervention group
Group type: COMPARATOR
Intervention: Background therapy
Number of subjects: 0
Study 34861154 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg per day
Number of subjects: 3730
Study 34861154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 34861408 — intervention group
Group type: EXPERIMENTAL
Intervention: HomeStyles intervention
Number of subjects: 0
Study 34861408 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet consisting of cereals and meat products
Number of subjects: 14
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre intake
Number of subjects: 14
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Red and processed meat intake
Number of subjects: 14
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-containing cereals intake
Number of subjects: 14
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate levels in faeces (absolute concentration)
Number of subjects: 14
Study 34861829 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate levels in faeces (relative abundance)
Number of subjects: 14
Study 34861829 — intervention group
Group type: COMPARATOR
Intervention: Levels of gluten immunogenic peptide and starch in faeces
Number of subjects: 14
Study 34862245 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line (given weekly for 4 weeks, then every 8 weeks until depletion or disease progression)
Number of subjects: 36
Study 34862245 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line
Number of subjects: 36
Study 34862279 — intervention group
Group type: COMPARATOR
Intervention: Community-based intervention to increase EOCRC awareness delivered via outdoor mass media and social media.
Number of subjects: 34
Study 34862279 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data analysis from Utah Cancer Registry and National Cancer Institute Surveillance, Epidemiology and End Results registry.
Number of subjects: 34
Study 34862279 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one interviews with EOCRC survivors.
Number of subjects: 34
Study 34862278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal povidone-iodine (PVI)
Number of subjects: 16
Study 34862278 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16
Study 34862289 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement learning-based text messaging programme
Number of subjects: 60
Study 34862289 — intervention group
Group type: COMPARATOR
Intervention: Control (standard text messaging)
Number of subjects: 60
Study 34862296 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective data collection from regular follow-up visits in a comprehensive database.
Number of subjects: 0
Study 34862296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised severity coding and grading of late effects according to the Common Terminology Criteria for Adverse Events version 4.0 modified by Hudson.
Number of subjects: 0
Study 34862297 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultation (VC) via telemedicine (TM)
Number of subjects: 2
Study 34862297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2
Study 34862297 — intervention group
Group type: EXPERIMENTAL
Intervention: VAMS device for blood ASM quantitation
Number of subjects: 2
Study 34862302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) performed by a CBT-trained cardiac nurse plus usual care
Number of subjects: 336
Study 34862302 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 336
Study 34862305 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism spectrum disorder
Number of subjects: 240
Study 34862305 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 240
Study 34862317 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-DoC patients
Number of subjects: 12
Study 34862449 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART4U smartphone application
Number of subjects: 666
Study 34862449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mHealth tool)
Number of subjects: 666
Study 34862470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric weight management interventions
Number of subjects: 407
Study 34862565 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SB-1 (sleep bruxers)
Number of subjects: 31
Study 34862565 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SB-2 (bruxers identified by Bruxoff device)
Number of subjects: 31
Study 34862565 — intervention group
Group type: COMPARATOR
Intervention: Group non-SB (non-sleep bruxers)
Number of subjects: 31
Study 34862565 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 31
Study 34862586 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed burst suppression (total burst suppression)
Number of subjects: 167
Study 34862586 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression ratio > 5 (SR > 5)
Number of subjects: 167
Study 34862586 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression ratio > 10 (SR > 10)
Number of subjects: 167
Study 34862586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline in composite z-score on the Alzheimer's Disease Research Center UDS Battery
Number of subjects: 167
Study 34862610 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis (AH)
Number of subjects: 439
Study 34862610 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score <15 by day 180
Number of subjects: 439
Study 34862610 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence by day 180
Number of subjects: 439
Study 34862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed after ERADICATE Hp trial
Number of subjects: 125
Study 34862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed after ERADICATE Hp2 trial
Number of subjects: 125
Study 34862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based therapies (CBT) prescribed for rapid CYP2C19 metabolizers
Number of subjects: 125
Study 34862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world prescription data for H. pylori infection
Number of subjects: 125
Study 34863019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Folinic Acid and Thyroid Hormone)
Number of subjects: 141
Study 34863019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 34863019 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups pooled for post-hoc analysis
Number of subjects: 141
Study 34863019 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GDQ
Number of subjects: 141
Study 34863025 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG3 donor-specific antibodies (dnDSA) from ABMR+ patients
Number of subjects: 54
Study 34863025 — intervention group
Group type: COMPARATOR
Intervention: IgG3 donor-specific antibodies (dnDSA) from ABMR- patients
Number of subjects: 54
Study 34863025 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictive factors of ABMR
Number of subjects: 54
Study 34863120 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive manual therapy mobilizations
Number of subjects: 38
Study 34863122 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare package including HIV, hepatitis B, and sexually transmitted infection management, pregnancy screening, and contraception
Number of subjects: 500
Study 34863122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile clinics for chronic/quarterly care
Number of subjects: 500
Study 34863122 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection waves including clinical, socio-behavioral, biological data, and in-depth interviews
Number of subjects: 500
Study 34863146 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE (Risk Stratification score)
Number of subjects: 0
Study 34863146 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC dyspnea score, pulmonary function tests (FEV)
Number of subjects: 0
Study 34863198 — intervention group
Group type: EXPERIMENTAL
Intervention: High autonomous profile (n=52)
Number of subjects: 169
Study 34863198 — intervention group
Group type: EXPERIMENTAL
Intervention: High combined profile (n=25)
Number of subjects: 169
Study 34863198 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate combined profile (n=92)
Number of subjects: 169
Study 34863216 — intervention group
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion
Number of subjects: 53
Study 34863240 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-II early years GCA score
Number of subjects: 55
Study 34863240 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-II early years GCA scores for 6 patients
Number of subjects: 55
Study 34863240 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-II school age GCA scores
Number of subjects: 55
Study 34863240 — intervention group
Group type: EXPERIMENTAL
Intervention: VABS-II Adaptive Behavior Composite (ABC) scores
Number of subjects: 55
Study 34863240 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-FOCUS
Number of subjects: 55
Study 34863245 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperFIT intervention activities implemented in the preschool setting
Number of subjects: 12
Study 34863245 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperFIT intervention
Number of subjects: 12
Study 34863252 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (information leaflet and workshops in a meeting room)
Number of subjects: 0
Study 34863252 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (information leaflet and workshops in a real apartment)
Number of subjects: 0
Study 34863252 — intervention group
Group type: COMPARATOR
Intervention: Control group (information leaflet on EDCs)
Number of subjects: 0
Study 34863252 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental health education intervention (workshops)
Number of subjects: 0
Study 34863255 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout-storytelling intervention
Number of subjects: 300
Study 34863255 — intervention group
Group type: COMPARATOR
Intervention: Stress reduction video
Number of subjects: 300
Study 34863258 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) 6000 IU
Number of subjects: 106
Study 34863258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 34863260 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with Xylitol (70% w/v) as the only sweetener
Number of subjects: 0